|Mr. Daniel N. Swisher Jr.||Chief Exec. Officer, Pres and Director||771.59k||N/A||54|
|Mr. Gene C. Jamieson||VP of Technical Operations||N/A||N/A||N/A|
|Dr. Judith A. Fox Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Dr. Deborah A. Thomas Ph.D.||Sr. VP of Regulatory Affairs, Quality Assurance & Non-Clinical Devel.||N/A||N/A||N/A|
|Mr. Parvinder S. Hyare||VP of Global Oncology Operations||N/A||N/A||N/A|
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome; and developing SNS-062, a non-covalently binding inhibitor of the human protein Brutons tyrosine kinase (BTK). The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Sunesis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.